- Exchange: NASDAQ GS
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Medical-Drugs
Snapshot for Alkermes PLC (ALKS)
| Open: | 15.8800 | Day's Range: | 15.7000 - 16.2100 | Volume: | 1,042,883 | Bid: | 16.1400 |
|---|---|---|---|---|---|---|---|
| Previous Close: | 15.9500 | 52wk Range: | 13.4800 - 20.0000 | 1-Yr Rtn: | -11.12% | Ask: | 16.1500 |
Key Statistics for ALKS
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E (03/2013) | 100.2484 |
| Earnings Per Share (USD) (ttm) | -0.3800 |
| Est. EPS (USD) (03/2013) | 0.1610 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 2,102.09 |
| Shares Outstanding (M) | 130.24 |
| Enterprise Value (M USD) (ttm) | 2,356.11 |
| Enterprise Value/EBITDA (ttm) | 436.07 |
| Price/Book (mrq) | 2.4679 |
| Price/Sale (ttm) | 4.8682 |
| Dividend Indicated Gross Yield | 0.0000 |
| Next Earnings Announcement | 08/01/2012 |
More ALKS Key Statistics
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Financials for ALKS
- Operating
- Investing
- Financing (M/USD)
Company Profile & Key Executives for ALKS
Alkermes PLC researches pharmaceuticals. The Company develops treatments for central nervous system disorders such as addiction, schizophrenia and depression, and diabetes.
| Richard F PopsChairman/President/CEO | Mark StejbachChief Commercial Officer |
| James M Frates "Jim"Senior VP/CFO/Treasurer | Gordon G PughSenior VP/COO/Chief Risk Ofcr |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Links
Top Forex Trading Resources
Advertisement
Advertisement
Advertisements
Rate this Page